Intermediate CAG repeat expansion in the ATXN2 gene is a unique genetic risk factor for ALS - A systematic review and meta-analysis of observational studies

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Wang, Ming Dong ^a   Gomes, James ^a   Cashman, Neil R ^b   Little, Julian ^a   Krewski, Daniel ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMYOTROPHIC LATERAL SCLEROSIS; ATXN2 GENE; CAG REPEAT; CAUCASIAN; DISEASE ACTIVITY; ETHNICITY; FAMILIAL DISEASE; GENE; GENETIC ASSOCIATION; GENETIC DIFFERENCE; GENETIC RISK; HUMAN; NEUROPATHOLOGY; OBSERVATIONAL STUDY; OUTCOMES RESEARCH; REVIEW; SYSTEMATIC REVIEW; GENETIC PREDISPOSITION; GENETICS; META ANALYSIS; MORTALITY; ONSET AGE; PREVALENCE; RISK; RISK FACTOR; TRINUCLEOTIDE REPEAT;

NERVE PROTEIN; SCA2 PROTEIN;

AGE OF ONSET; AMYOTROPHIC LATERAL SCLEROSIS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MORTALITY; NERVE TISSUE PROTEINS; ODDS RATIO; PREVALENCE; RISK FACTORS; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 84928761808     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0105534     Document Type: Review

References (83)

1. Talman P, Forbes A, Mathers S (2009) Clinical phenotypes and natural progression for motor neuron disease: analysis from an Australian database. Amyotroph Lateral Scler 10: 79-84.
2. Al-Chalabi A, Fang F, Hanby MF, Leigh PN, Shaw CE, et al. (2010) An estimate of amyotrophic lateral sclerosis heritability using twin data. Journal of neurology, neurosurgery, and psychiatry, December 01 PMC2988617: 1324-1326.
3. Wingo TS, Cutler DJ, Yarab N, Kelly CM, Glass JD (2011) The heritability of amyotrophic lateral sclerosis in a clinically ascertained United States research registry. PLoS One 6:e27985.
4. Al-Chalabi A, Jones A, Troakes C, King A, Al-Sarraj S, et al. (2012) The genetics and neuropathology of amyotrophic lateral sclerosis. Acta Neuropathol 124: 339-352.
5. Al-Chalabi A, Lewis CM (2011) Modelling the effects of penetrance and family size on rates of sporadic and familial disease. Hum Hered 71: 281-288.
6. Baumer D, Talbot K, Turner MR (2014) Advances in motor neurone disease. J R Soc Med 107: 14-21.
7. Renton AE, Chio A, Traynor BJ (2014) State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci 17: 17-23.
8. Ripps ME, Huntley GW, Hof PR, Morrison JH, Gordon JW (1995) Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 92: 689-693.
9. ALS Online Genetics Database, World Federation of Neurology and European Network to Cure ALS (Jan. 2014) 2014.
10. Mulligan VK, Chakrabartty A (2013) Protein misfolding in the late-onset neurodegenerative diseases: common themes and the unique case of amyotrophic lateral sclerosis. Proteins 81: 1285-1303.
11. Jones CT, Brock DJ, Chancellor AM, Warlow CP, Swingler RJ (1993) Cu/Zn superoxide dismutase (SOD1) mutations and sporadic amyotrophic lateral sclerosis. Lancet 342: 1050-1051. (Pubitemid 23314817)
12. Ticozzi N, Tiloca C, Morelli C, Colombrita C, Poletti B, et al. (2011) Genetics of familial amyotrophic lateral sclerosis. Arch Ital Biol 149: 65-82.
13. Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, et al. (2011) A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72: 257-268.
14. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, et al. (2011) Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72: 245-256.
15. Rademakers R, van Blitterswijk M (2013) Motor neuron disease in 2012: Novel causal genes and disease modifiers. Nat Rev Neurol 9: 63-64.
16. Cruts M, Gijselinck I, Van Langenhove T, van der Zee J, Van Broeckhoven C (2013) Current insights into the C9orf72 repeat expansion diseases of the FTLD/ALS spectrum. Trends Neurosci 36: 450-459.
17. Smith BN, Newhouse S, Shatunov A, Vance C, Topp S, et al. (2013) The C9ORF72 expansion mutation is a common cause of ALS+/-FTD in Europe and has a single founder. Eur J Hum Genet 21: 102-108.
18. Tsai CP, Soong BW, Tu PH, Lin KP, Fuh JL, et al. (2012) A hexanucleotide repeat expansion in C9ORF72 causes familial and sporadic ALS in Taiwan. Neurobiol Aging 33: 2232.e11-2232.e18.
19. Konno T, Shiga A, Tsujino A, Sugai A, Kato T, et al. (2013) Japanese amyotrophic lateral sclerosis patients with GGGGCC hexanucleotide repeat expansion in C9ORF72. J Neurol Neurosurg Psychiatry 84: 398-401.
20. Alavi A, Nafissi S, Rohani M, Shahidi G, Zamani B, et al. (2014) Repeat expansion in C9ORF72 is not a major cause of amyotrophic lateral sclerosis among Iranian patients. Neurobiol Aging 35: 267.e1-267.e7.
21. Zou ZY, Li XG, Liu MS, Cui LY (2013) Screening for C9orf72 repeat expansions in Chinese amyotrophic lateral sclerosis patients. Neurobiol Aging 34: 1710.e5-1710.e6.
22. Liu Y, Yu JT, Zong Y, Zhou J, Tan L (2014) C9ORF72 mutations in neurodegenerative diseases. Mol Neurobiol 49: 386-398.
23. Jiao B, Tang B, Liu X, Yan X, Zhou L, et al. (2014) Identification of C9orf72 repeat expansions in patients with amyotrophic lateral sclerosis and frontotemporal dementia in mainland China. Neurobiol Aging 35: 936.e19-936.e22.
24. Majounie E, Renton AE, Mok K, Dopper EG, Waite A, et al. (2012) Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol 11: 323-330.
25. van Blitterswijk M, Mullen B, Heckman MG, Baker MC, DeJesus-Hernandez M, et al. (2014) Ataxin-2 as potential disease modifier in C9ORF72 expansion carriers. Neurobiol Aging.
26. Polymenidou M, Lagier-Tourenne C, Hutt KR, Bennett CF, Cleveland DW, et al. (2012) Misregulated RNA processing in amyotrophic lateral sclerosis. Brain Res 1462: 3-15.
27. Lill CM, Abel O, Bertram L, Al-Chalabi A (2011) Keeping up with genetic discoveries in amyotrophic lateral sclerosis: The ALSoD and ALSGene databases. Amyotroph Lateral Scler 12: 238-249.
28. PRIZE4LIFE (nd) ALSgene. Available at: http://www.alsgene.org/. Accessed 2014 Jan 25.
29. Al-Chalabi A, Hardiman O (2013) The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol 9: 617-628.
30. Meireles A, Al-Chalabi A (2009) Genetic studies of amyotrophic lateral sclerosis: Controversies and perspectives. Amyotrophic Lat Scler 10: 1-14.
31. Johnson F, Atchison W (2009) The role of environmental mercury, lead and pesticide exposure in development of amyotrophic lateral sclerosis. Neurotoxicology 30: 761-765.
32. Sutedja NA, Veldink JH, Fischer K, Kromhout H, Heederik D, et al. (2009) Exposure to chemicals and metals and risk of amyotrophic lateral sclerosis: a systematic review. Amyotroph Lateral Scler 10: 302-309.
33. Sutedja NA, Fischer K, Veldink JH, van der Heijden GJMG, Kromhout H, et al. (2009) What we truly know about occupation as a risk factor for ALS: a critical and systematic review. Amyotrophic lateral sclerosis: official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases 10: 295-301.
34. Ahmed A, Wicklund MP (2011) Amyotrophic lateral sclerosis: what role does environment play? Neurol Clin 29: 689-711.
35. Migliore L, Coppede F (2009) Genetics, environmental factors and the emerging role of epigenetics in neurodegenerative diseases. Mutat Res 667: 82-97.
36. Abel O, Powell JF, Andersen PM, Al-Chalabi A (2012) ALSoD: A user-friendly online bioinformatics tool for amyotrophic lateral sclerosis genetics. Hum Mutat 33: 1345-1351.
37. Wills AM, Cronin S, Slowik A, Kasperaviciute D, Van Es MA, et al. (2009) A large-scale international meta-analysis of paraoxonase gene polymorphisms in sporadic ALS. Neurology 73: 16-24.
38. van Rheenen W, Diekstra FP, van Doormaal PT, Seelen M, Kenna K, et al. (2013) H63D polymorphism in HFE is not associated with amyotrophic lateral sclerosis. Neurobiol Aging 34: 1517.e5-1517.e7.
39. Sutedja NA, Sinke RJ, Van Vught PW, Van der Linden MW, Wokke JH, et al. (2007) The association between H63D mutations in HFE and amyotrophic lateral sclerosis in a Dutch population. Arch Neurol 64: 63-67. (Pubitemid 46072425)
40. Lambrechts D, Poesen K, Fernandez-Santiago R, Al-Chalabi A, Del Bo R, et al. (2009) Meta-analysis of vascular endothelial growth factor variations in amyotrophic lateral sclerosis: increased susceptibility in male carriers of the-2578AA genotype. J Med Genet 46: 840-846.
41. Dejesus-Hernandez M, Rayaprolu S, Soto-Ortolaza AI, Rutherford NJ, Heckman MG, et al. (2013) Analysis of the C9orf72 repeat in Parkinson's disease, essential tremor and restless legs syndrome. Parkinsonism Relat Disord 19: 198-201.
42. Garcia-Redondo A, Dols-Icardo O, Rojas-Garcia R, Esteban-Perez J, Cordero-Vazquez P, et al. (2013) Analysis of the C9orf72 gene in patients with amyotrophic lateral sclerosis in Spain and different populations worldwide. Hum Mutat 34: 79-82.
43. Elden AC, Kim H, Hart MP, Chen-Plotkin AS, Johnson BS, et al. (2010) Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 466: 1069-1075.
44. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62:e1-34.
45. Downs SH, Black N (1998) The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 52: 377-384. (Pubitemid 28438523)
46. Laffita-Mesa JM, Rodriguez Pupo JM, Moreno Sera R, Vazquez Mojena Y, Kouri V, et al. (2013) De Novo Mutations in Ataxin-2 Gene and ALS Risk. PLoS One 8:e70560.
47. Corrado L, Mazzini L, Oggioni GD, Luciano B, Godi M, et al. (2011) ATXN-2 CAG repeat expansions are interrupted in ALS patients. Hum Genet 130: 575-580.
48. Conforti FL, Spataro R, Sproviero W, Mazzei R, Cavalcanti F, et al. (Dec 2012) Ataxin-1 and ataxin-2 intermediate-length PolyQ expansions in amyotrophic lateral sclerosis. Neurology 79: 2315-2320.
49. Bonini NM, Gitler AD (2011) Model organisms reveal insight into human neurodegenerative disease: ataxin-2 intermediate-length polyglutamine expansions are a risk factor for ALS. J Mol Neurosci 45: 676-683.
50. Ross OA, Rutherford NJ, Baker M, Soto-Ortolaza AI, Carrasquillo MM, et al. (2011) Ataxin-2 repeat-length variation and neurodegeneration. Hum Mol Genet 20: 3207-3212.
51. Van Langenhove T, van der Zee J, Engelborghs S, Vandenberghe R, Santens P, et al. (May 2012) Ataxin-2 polyQ expansions in FTLD-ALS spectrum disorders in Flanders-Belgian cohorts. Neurobiol Aging 33:e17-e20.
52. Gellera C, Ticozzi N, Pensato V, Nanetti L, Castucci A, et al. (Aug 2012) ATAXIN2 CAG-repeat length in Italian patients with amyotrophic lateral sclerosis: Risk factor or variant phenotype? Implication for genetic testing and counseling. Neurobiol Aging 33:e15-e21.
53. Lee T, Li YR, Chesi A, Hart MP, Ramos D, et al. (Jun 2011) Evaluating the prevalence of polyglutamine repeat expansions in amyotrophic lateral sclerosis. Neurology 76: 2062-2065.
54. Daoud H, Belzil V, Martins S, Sabbagh M, Provencher P, et al. (Jun 2011) Association of long ATXN2 CAG repeat sizes with increased risk of amyotrophic lateral sclerosis. Arch Neurol 68: 739-742.
55. Van Damme P, Veldink JH, van Blitterswijk M, Corveleyn A, van Vught PW, et al. (2011) Expanded ATXN2 CAG repeat size in ALS identifies genetic overlap between ALS and SCA2. Neurology 76: 2066-2072.
56. Lee T, Li YR, Ingre C, Weber M, Grehl T, et al. (2011) Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients. Hum Mol Genet 20: 1697-1700.
57. Gispert S, Kurz A, Waibel S, Bauer P, Liepelt I, et al. (2012) The modulation of Amyotrophic Lateral Sclerosis risk by Ataxin-2 intermediate polyglutamine expansions is a specific effect. Neurobiol Dis 45: 356-361.
58. Liu X, Lu M, Tang L, Zhang N, Chui D, et al. (Sep 2013) ATXN2 CAG repeat expansions increase the risk for Chinese patients with amyotrophic lateral sclerosis. Neurobiol Aging 34:e5-e8.
59. Chen Y, Huang R, Yang Y, Chen K, Song W, et al. (Oct 2011) Ataxin-2 intermediate-length polyglutamine: A possible risk factor for Chinese patients with amyotrophic lateral sclerosis. Neurobiol Aging 32:e1-e5.
60. Laffita J, Bauer PO, Kouri V, Pena Serrano L, Roskams J, et al. (2012) Epigenetic DNA-methylation in the core ataxin-2 gene promoter: Novel physiological and pathological implications. Parkinsonism and Related Disorders 18:S187.
61. Lahut S, Omur O, Uyan O, Agim ZS, Ozoguz A, et al. (2012) ATXN2 and its neighbouring gene SH2B3 are associated with increased ALS risk in the Turkish population. PLoS One 7:e42956.
62. Yu Z, Zhu Y, Chen-Plotkin AS, Clay-Falcone D, McCluskey L, et al. (2011) PolyQ repeat expansions in ATXN2 associated with ALS are CAA interrupted repeats. PLoS One 6:e17951.
63. Hart MP, Gitler AD (Jul 2012) ALS-associated ataxin 2 polyQ expansions enhance stress-induced caspase 3 activation and increase TDP-43 pathological modifications. The Journal of Neuroscience 32: 9133-9142.
64. Drost J, Nonis D, Eich F, Leske O, Damrath E, et al. (2013) Ataxin-2 modulates the levels of Grb2 and SRC but not ras signaling. J Mol Neurosci 51: 68-81.
65. Gispert S, Kurz A, Waibel S, Bauer P, Liepelt I, et al. (2012) The modulation of Amyotrophic Lateral Sclerosis risk by ataxin-2 intermediate polyglutamine expansions is a specific effect. Neurobiol Dis 45: 356-361.
66. Chen X, Sun H, Zhang C, Zhang Y, Lin K, et al. (2013) Positive selection of CAG repeats of the ATXN2 gene in Chinese ethnic groups. Journal of Genetics and Genomics 40: 543-548.
67. Geschwind DH, Perlman S, Figueroa CP, Treiman LJ, Pulst SM (1997) The prevalence and wide clinical spectrum of the spinocerebellar ataxia type 2 trinucleotide repeat in patients with autosomal dominant cerebellar ataxia. Am J Hum Genet 60: 842-850. (Pubitemid 27146492)
68. Soraru G, Clementi M, Forzan M, Orsetti V, D'Ascenzo C, et al. (Jun 2011) ALS risk but not phenotype is affected by ataxin-2 intermediate length polyglutamine expansion. Neurology 76: 2030-2031.
69. Laffita-Mesa JM, Velazquez-Perez LC, Santos Falcon N, Cruz-Marino T, Gonzalez Zaldivar Y, et al. (2012) Unexpanded and intermediate CAG polymorphisms at the SCA2 locus (ATXN2) in the Cuban population: evidence about the origin of expanded SCA2 alleles. Eur J Hum Genet 20: 41-49.
70. Costanzi-Porrini S, Tessarolo D, Abbruzzese C, Liguori M, Ashizawa T, et al. (2000) An interrupted 34-CAG repeat SCA-2 allele in patients with sporadic spinocerebellar ataxia. Neurology 54: 491-493. (Pubitemid 30078091)
71. Fernandez M, McClain ME, Martinez RA, Snow K, Lipe H, et al. (2000) Lateonset SCA2: 33 CAG repeats are sufficient to cause disease. Neurology 55: 569-572. (Pubitemid 30647259)
72. Tazen S, Figueroa K, Kwan JY, Goldman J, Hunt A, et al. (2013) Amyotrophic lateral sclerosis and spinocerebellar ataxia type 2 in a family with full CAG repeat expansions of ATXN2. Movement Disorders 28:S241-S242.
73. Gispert S, Twells R, Orozco G, Brice A, Weber J, et al. (1993) Chromosomal assignment of the second locus for autosomal dominant cerebellar ataxia (SCA2) to chromosome 12q23-24.1. Nat Genet 4: 295-299. (Pubitemid 23205180)
74. Magana JJ, Velazquez-Perez L, Cisneros B (2013) Spinocerebellar ataxia type 2: clinical presentation, molecular mechanisms, and therapeutic perspectives. Mol Neurobiol 47: 90-104.
75. Farg MA, Soo KY, Warraich ST, Sundaramoorthy V, Blair IP, et al. (2013) Ataxin-2 interacts with FUS and intermediate-length polyglutamine expansions enhance FUS-related pathology in amyotrophic lateral sclerosis. Hum Mol Genet 22: 717-728.
76. Lattante S, Rouleau GA, Kabashi E (2013) TARDBP and FUS mutations associated with amyotrophic lateral sclerosis: summary and update. Hum Mutat 34: 812-826.
77. Hart MP, Brettschneider J, Lee VMY, Trojanowski JQ, Gitler AD (Aug 2012) Distinct TDP-43 pathology in ALS patients with ataxin 2 intermediate-length polyQ expansions. Acta Neuropathol 124: 221-230.
78. Andersen PM, Forsgren L, Binzer M, Nilsson P, Ala-Hurula V, et al. (1996) Autosomal recessive adult-onset amyotrophic lateral sclerosis associated with homozygosity for Asp90Ala CuZn-superoxide dismutase mutation. A clinical and genealogical study of 36 patients. Brain 119 (Pt 4):1153-1172. (Pubitemid 26300718)
79. Choudhry S, Mukerji M, Srivastava AK, Jain S, Brahmachari SK (2001) CAG repeat instability at SCA2 locus: anchoring CAA interruptions and linked single nucleotide polymorphisms. Hum Mol Genet 10: 2437-2446. (Pubitemid 33069549)
80. Ramos EM, Keagle P, Gillis T, Lowe P, Mysore JS, et al. (2012) Prevalence of Huntington's disease gene CAG repeat alleles in sporadic amyotrophic lateral sclerosis patients. Amyotrophic Lat Scler 13: 265-269.
81. Ramos EM, Martins S, Alonso I, Emmel VE, Saraiva-Pereira ML, et al. (2010) Common origin of pure and interrupted repeat expansions in spinocerebellar ataxia type 2 (SCA2). Am J Med Genet B Neuropsychiatr Genet 153B:524-531.
82. BragaNeto P, Pedroso JL, Felicio AC, Abrahao A, Dutra LA, et al. (Apr 2011) SCA2 presenting as an ataxia-Parkinsonism-motor neuron disease syndrome. Arq Neuropsiquiatr 69(:405-406.
83. Qureshi AI, Wilmot G, Dihenia B, Schneider JA, Krendel DA (1996) Motor neuron disease with parkinsonism. Arch Neurol 53: 987-991. (Pubitemid 26340033)